Litcius/Paper detail

854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

Y. Tao, A. Aupérin, Xinzhi Sun, X. Liem, C. Sire, Laurent Martin, Y. Pointreau, Christian Borel, M-C. Kaminsky-Forrett, J. Miroir, Frédéric Rolland, Alexandre Coutté, F. Clatot, Laura Sinigaglia, Juliette Thariat, Caroline Even, Esma Saâda, J. Guigay, Jean Bourhis

2024Annals of Oncology17 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCetuximabOncologyHead and neckAvelumabInternal medicineRadiation therapyHead and neck cancerHead and neck squamous-cell carcinomaCancerImmunotherapySurgeryPembrolizumabColorectal cancerHead and Neck Cancer StudiesRadiopharmaceutical Chemistry and ApplicationsLung Cancer Treatments and Mutations
854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial | Litcius